Th e aim of this study was to investigate changes in serum nitric oxide (NO) concentration in infl ammatory bowel diseases (IBD) patients and its use as potential biomarker in diff erential diagnosis of ulcerative colitis (UC) and Crohn' s disease (CD) and in disease activity assessment. In  patients of both genders - with ulcerative colitis and  with Crohn' s disease -and  controls serum nitric oxide concentration was determined by measuring nitrite concentration, a stable metabolic product of NO with oxygen. Conversion of nitrates (NO -) to nitrites (NO -) was done with elementary zinc. Th e nitrite concentration was determined by classic colorimetrical Griess reaction. Median serum NO concentration was statistically diff erent (p=,) between UC patients (. μmol/L; . -. μmol/L), CD patients (. μmol/L; . -. μmol/L) and healthy controls (. μmol/L; . -. μmol/L). When active UC and CD patients were compared with inactive UC and CD patients respectively a signifi cant diff erence in serum NO level was found (p=.). With a cut-off level of . μmol/L NO had a sensitivity of  and a specifi city of  in discriminating between active and inactive UC patients. With cut-off value of . μmol/L serum NO level had a sensitivity of  and a specifi city of  in distinguishing between patients with active CD and inactive CD. Serum NO concentration is a minimally invasive and rapid tool for discriminating between active and inactive IBD patients and could be used as useful biomarker in monitoring of disease activity in IBD patients.
INTRODUCTION
NO is a free radical gas messenger molecule with both intraand extracellular regulatory functions for many cells. Endogenous NO is generated from the L-arginine by oxidation of terminal nitrogen in the guanidine group in reaction catalyzed by the enzyme nitric oxide synthase (NOS) [] . Two distinct functional forms of NOS can be recognized: constitutive and the inducible forms. NO synthesis by the constitutive isoforms, endothelial (eNOS) and neuronal (nNOS), generate low levels of NO under normal physiological conditions [, ] . In the gastrointestinal tract (GIT) constitutive isoforms found in the endothelial cells (eNOS) and certain nerve terminals (nNOS) innervating the colon, regulate blood fl ow and bowel motility by promoting muscle relaxation of the vessels and the bowel, respectively [] . Th ird isoform inducible (iNOS) is highly expressed in macrophages, neutrophiles, endothelial and smooth muscle cells upon diff erent stimuli. After induction by endotoxine and/or cytokine, iNOS generates high, sustained levels of NO. Th ese elevated levels of NO may be toxic and may damage healthy tissue. Tissue injury may result from an interaction of NO with superoxide anion, one of the reactive oxygen species, resulting in a formation of peroxynitrite that further contributes to tissue damage and up-regulation of the infl ammatory response [, ] . Infl ammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD) are idiopathic, chronic and remitting infl ammatory diseases of gastrointestinal tract. Clinical symptoms, endoscope fi ndings, hystopathological characteristics and immunopathophysiology diff er among them [] . Despite extensive investigation the etiology and pathogenesis of human IBD remains unknown. Previous experimental and clinical studies have suggested that the initiation and pathogenesis of IBD are multifactorial and involve interaction between genetic, environmental, infective and immunological factors. cal factors in the infl ammatory process of these diseases [] . Numerous manifestations of IBD which include: vasodilation in the mucosa, increased vascularand epithelial permeability and motility disorders are related with direct or indirect eff ects of NO. Th ere is comprehensive evidence of an increased production of NO in IBD. Reynolds etal. [] have found increased levels of NO in the lumen of the colon in patients with active UC. Similar data were obtained Ljung et al. [] who found rectal NO increased in patients with active UC and CD. Although previous studies have only noticed the increased activity of NOS in the intestinal mucosa in patients with UC [] , subsequent work showed increased NO production in the mucosa in patients with CD [] . Th e results of recent studies support the hypothesis that NO is an important etiological factor for the development of chronic infl ammatory bowel disease and ulcerative colitis. Increased concentrations of NO and iNOS overexpression were found in altered infl ammatory mucosa of patients with IBD, which may contribute to the process of deterioration and exacerbation of immune responses [] . Active inflammation of the colon lining is associated with increased production of cytokines (TNF-α, IL- and IFN-γ) that are released by infl ammatory cells (macrophages and neutrophils), endothelial cells and smooth muscles of the digestive tract. These cytokines induce iNOS, which causes an increased release of NO and the consequent creation of reactive products such as peroxynitrite,hydrogen peroxide and superoxide anions. Peroxynitrite exert cytotoxic effects and can cause membrane lipid peroxidation with an additional increase in permeability, causing breakdown ofDNA chains and activation of poly (ADP ribose) -synthase, which leads to energy consumption and impairment of intracellular ATP. Peroxynitrite once formed causes tissue damage and infl ammation [, ] . Since NO can be measured with the use of non-invasive methods, the aim of this study was toexamine the possibility of its usage as potential serological marker in differential diagnosis of IBD, and in IBD activity assessment.
MATERIALS AND METHODS
Patients Th e study included  patients with ulcerative colitis (UC) and  patients with Crohn's disease (CD). Based on UC activity index (UCAI) defi ned by Seo et al. [] and Activity index (AI) for CD patients defined by Van Hees et al. [] studied groups were divided into subgroups of those displaying the active and inactive phases of the disease. Control group (n=) represented age and gender-matched, apparently healthy individuals. All subjects involved in the study went through detailed anamnestic questionnaire, medical history, physical examination and standard laboratory analyses. Written informed consent was obtained from all of the study participants. Th e study was carried out at the Institute for Physiology and Biochemistry of Faculty of Medicine in Sarajevo, with an approval from the Local Ethic Committee. Investigations were carried out in accordance with the Declaration of Helsinki as revised in .
NO measurement
The serum nitric oxide concentration was determined by measuring nitrite concentration, a stable metabolic product of NO with oxygen. Conversion of nitrates (NO -) to nitrites (NO -) was done with elementary zinc. Th e nitrite concentration was determined by classic colorimetrical Griess reaction [] . Blood samples for the determination of serum NO levels were taken from the cubital vein and allowed to coagulate. After coagulation the samples were centrifuged at  g for  min, and the serum samples were deproteinized by adding  μl of distilled water and  μl of  ZnSO to  μl of each serum sample. Samples were further centrifuged at g for  min and frozen at -  C until the analysis was performed. Th e procedure included suspending  mg of elemental zinc in  μl of distilled water and adding it to  μl of supernatants. Also,  μl of  acetic acid and  μl of distilled water were added to it, thus reaching the total volume of  ml. Samples prepared in this way were put on a vortex for  minutes at room temperature and centrifuged at  g for . minutes. Th en,  μl of supernatant was mixed with an equal volume of the Griess reagent. Th e Griess reagent consists of equal volumes of . naphthylethylene diamine dihydrochloride in distilled water and  sulfanilamide in  HPO. Th ese two components were mixed  hours prior to usage and stored in a cold place. Th e supernatants and the Griess reagent mixtures were put on a vortex for  minutes and the light absorbance (optical density) was measured with a spectrophotometer at  nm. Th e nitrate concentration was read from the standard curve with a known NaNO concentration (ranging from . - μmol). Blind samples were composed of the Griess reagent and distilled water.
Statistical analysis
The Shapiro-Wilk test of normality was used to test the distribution of variables. Since all variables were skewed they are presented as median and interquartile ranges. Th e difference in values of tested parameters was assessed by Kruskal-Wallis test. Afterwards, Mann-Whithey U-test was used to compare differences between two groups. A p value of <. was considered statistically significant. Sensitivity, specifi city, positive and negative predictive value were calculated according to the following formula [] Receiver operating characteristic (ROC) curves were constructed by calculating the sensitivities and specificities of serum NO concentration at several cut-off points. Th e software used was SPSS for Windows (version .; SPSS, Chicago, IL, USA).
RESULTS

Serum nitric oxide concentration
Serum NO concentration of the studied five groups are showed in Figure  Figure  . Serum NO level was the most accurate for differentiating patients with active UC from patients with inactive UC (AUC .). For differentiation between patients with active and inactive CD or differentiation between IBD patients and healthy controls serum NO level also had a good diagnostic accuracy (AUC . and .). Based on the proposed cut-off values, the sensitivity and specificity of the serum NO concentration were calculated. Table . shows the predictive power of serum NO level in distinguishing patients with IBD and healthy controls, active UC patients from inactive UC patients and active CD patients from inactive CD patients.
DISCUSSION
Th e immunology of IBD continues to be an intense area of investigations for clues to the pathogenesis of ulcerative colitis and Crohn's disease. Typical for complex diseases, IBD research is continuously evolving. Without abandoning traditional areas of study, such as cellular and humoral immunity and cytokines, examination is broadening to explore new molecules and biologic phenomena [] . Infl ammatory mediators, cytokines, free radicals, as well as mucosal immune system provide a basis not only for the understanding of in-FIGURE 1. Box-and-whisker plots of serum NO levels (μmol/L) in the fi ve studied groups. The solid horizontal lines denote the median value, the box represents the 25% and 75% interquartile ranges and the whiskers represent minimum and maximum values. N = normal, healthy control; iCD = inactive Crohn's disease; aCD = active Crohn's disease; iUC = inactive ulcerative colitis; aUC = active ulcerative colitis. It is now widely held that oxidants, including free radicals, such as nitric oxide, play a key role in the pathophysiology of tissue injury in IBD, particularly in the initiation and perpetuation of infl ammation and in the subsequent tissue damage [, ] . Th e aim of this study was to investigate changes in serum NO concentration and the possibility of its use as potential serum biomarker in disease activity assessment and in differential diagnosis of ulcerative colitis and Crohn's disease. The reasons why we examined serum NO concentration as a potential laboratory marker in IBD was: fi rstly, to gain an objective measurement of disease activity as symptoms are often subjective; and secondly, to avoid invasive (endoscopic) procedures which are often a burden to the patient. Th e results of our study showed that the serum NO level was signifi cantly higher in IBD patients compared to the control group (p=.). Although the serum NO concentration was higher in UC patients compared to CD patients, there was no statistically signifi cant diff erence between the compared groups (p=.). Our results are in the accordance with the results of Oudkerk et al. [] who also found no statistically signifi cant diff erence in the median serum NO concentration between patients with UC and CD patients. However, when we compared active UC patients with inactive UC patients we found a statistically signifi cant diff erence in serum NO level (p=.). Comparing active CD patients with inactive CD patients we also found a signifi cant diff erence in serum NO concentration (p=.). Our results confi rm fi ndings from previous studies such as the study by Oudkerk et al. [] who also observed signifi cant higher serum NO level in UC and CD patients in active phase of the disease compared to inactive phase. Numerous experimental studies have shown raised NO concentrations in active phase of disease not only in serum but also in stool [] , urine [] and in the lumen of the rectum [] in patients with IBD. Levine et al. [] conducted a study which demonstrated that IBD patients with active colitis have increased stool and plasma NO concentration compared to IBD patients with normal colonic histology and those with mild, nonspecifi c colonic infl ammation. Goggins et al. [] demonstrated that urinary nitrite concentration, a stable end product of NO in patients with active IBD were significanty diff erent from levels in inactive IBD patients. Th ese authors suggest that measurement of urinary nitrite may serve as a useful marker for monitoring disease activity in IBD. Based on the significant difference in serum NO level between active IBD and inactive IBD patients, an attempt was made to diff erentiate active and inactive IBD patients. For clinical decision making, the selected cut-off value of a laboratory test should provide the best diagnostic performance for either ruling out or ruling in the particular disease. Th e ROC curve analysis is a graphic method which can be used to determine this optimal cut-off level. In addition, it is a precise and valid measure of diagnostic accuracy [] . In this study, based on the selected optimal cut-off value by ROC curve analysis, serum NO level showed a high specificity () and high sensitivity () in distinguishing patients with active UC from inactive UC patients; moderate specificity () and a good sensitivity () in distinguishing patients with active CD from inactive CD patients. We further tested whether serum NO level, as a serological marker, could help in diff erentiating patiens with ulcerative colitis and Cronh's disease. Our study has not demonstrated a statistically signifi cant diff erence in NO level between ulcerative colitis and Cronh's disease (p=.), even though the patients with ulcerative colitis had higher serum NO levels compared to the patients with Crohn's disease. Th e lack of such diff erence may be due to diff erent distribution and ac- tivation of iNOS in these patients. Earlier study by Middelton et al. [] has shown a marked increase in NO synthase activity only in the infl amed colonic mucosa of patients with ulcerative colitis. Th e cellular source of iNOS isoform in the infl amed mucosa may be product of resident or infi ltrating leucocytes (neutrophils or macrophages) or mucosal vascular smooth muscle or endothelium. Induction of iNOS in these cells may occur due to stimulatory cytokines (TNF and IL-), the mucosal levels of which are increased in ulcerative colitis [] . In contrast to ulcerative colitis, there was no increase in NO synthase activity detected in the infl amed colonic mucosa from patients with Crohn's disease, suggesting that there is no induction of NO synthase in the colon in this infl ammatory bowel disease [] . Th e failure to detect induction of NO synthase in the infl amed tissue of Crohn's disease patients may refl ect a defi ciency in the induction process or could be due to mucosal formation of inhibitory cytokines such as IL- or IL-, which can prevent NO synthase induction. Th e balance of stimulatory versus inhibitory cytokines could determine the expression of NO synthase in both ulcerative colitis and Crohn's disease.
CONCLUSION
Significant serum NO concentration increment during the active phase of disease and decrease during the inactive phase conveys possible use of serum NO level for monitoring disease activity in both types of IBD. Due to an absence of significant differences in serum NO concentration among patients with UC and CD, serum NO can not be recommended for IBD differential diagnosis use.
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